Table 1.
Characteristics of Study Population at Week 12 (N=1496)
| Mean age, years (SD) | 39.3 (9.2) |
| Male, N (%) | 1275 (85.2) |
| Race/ethnicity, N (%) | |
| White | 756 (50.5) |
| Black | 426 (28.5) |
| Latino | 264 (17.7) |
| Other | 50 (3.3) |
| HIV risk behavior, N (%)b | |
| MSM | 798 (61.0) |
| Heterosexual | 316 (24.1) |
| Needle sharing | 69 (5.3) |
| Transfusion | 28 (2.1) |
| Other/do not know | 98 (7.5) |
| Treatment naïve, N (%) | 792 (52.9) |
| Study protocol number, N (%) | |
| ACTG 371a | 102 (6.8) |
| ACTG 372 | 42 (2.8) |
| ACTG 384a | 358 (23.9) |
| ACTG 398 | 278 (18.6) |
| ACTG 400 | 21 (1.4) |
| ACTG 746a | 101 (6.8) |
| A5025 | 168 (11.2) |
| A5073a | 231 (15.4) |
| A5116 | 132 (8.8) |
| A5126 | 21 (1.4) |
| A5143 | 42 (2.8) |
| Mean CD4+ cell count, cells/mL (SD)c | 402.2 (265.2) |
| Plasma HIV RNA below limit of quantification, N (%) | 694 (46.5) |
| Barriers to adherence, N (%) | |
| Away from home | 328 (21.9) |
| Simply forgot | 293 (19.6) |
| Change in daily routine | 292 (19.5) |
| Fell asleep/slept through dose time | 282 (18.9) |
| Busy with other things | 255 (17.1) |
| Felt sick or ill | 186 (12.4) |
| Problem taking pills at specified time | 181 (12.1) |
| Wanted to avoid side effects | 133 (8.9) |
| Felt depressed/overwhelmed | 127 (8.5) |
| Felt good | 111 (7.4) |
| Not want others to notice you taking medications | 105 (7.0) |
| Felt like the drug was toxic/harmful | 82 (5.5) |
| Too many pills to take | 79 (5.3) |
| Ran out of pills | 48 (3.2) |
| Summed adherence barriers, N (%) | |
| 0 (no ACTG barriers reported) | 845 (56.5) |
| 1 (1–4 ACTG barriers reported) | 446 (29.8) |
| 2 (≥5 ACTG barriers reported) | 205 (13.7) |
ACTG, AIDS Clinical Trials Group; ART, antiretroviral therapy; MSM, men who have sex with men; SD, standard deviation.
a
ACTG ART naïve studies; bN=1309; cN=1483.